Moleculin Biotech, Inc. stockholders approved a Nasdaq proposal for warrant-related share issuance and an adjournment proposal but did not approve a proposal to change the company's name at a special meeting held on April 15, 2026.
Key takeaways
Stockholders approved the issuance of up to 6,367,956 shares upon exercise of certain warrants issued on February 20, 2026.
Stockholders did not approve an amendment to change the company's name from Moleculin Biotech, Inc. to Moleculin Inc.
Stockholders approved an adjournment proposal to solicit additional proxies if needed for the Nasdaq or Name Change proposals.
The record date for the special meeting was February 20, 2026, with 4,933,110 shares outstanding and 2,382,989 shares present constituting a quorum.